CoChat
Sign Up
Cited by 127

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis

Magen, Iddo, Yacovzada, Nancy Sarah, Yanowski, Eran, Coenen-Stass, Anna, Grosskreutz, Julian, Lu, Ching-Hua, Greensmith, Linda, Malaspina, Andrea, Fratta, Pietro, Hornstein, Eran·2021·Nature Neuroscience
DOI 10.1038/s41593-021-00936-z

Published version of a preprint

Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41593-021-00936-z

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Dysregulation of microRNAs has been observed in various neurodegenerative and neuropsychiatric diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, schizophrenia, and depression.

    “Dysregulation of miRs has been observed in various neurodegenerative and neuropsychiatric diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), schizophrenia, and depression [13–19].”

    From A role for astrocytic miR-129-5p in frontotemporal dementia (2025) · cites this paper as [15]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 46

  1. Munsat, T. L., Andres, P. L., Finison, L., Conlon, T. & Thibodeau, L. The natural history of motoneuron loss in amyotrophic lateral sclerosis. Neurology 38, 409–413 (1988). · DOI
  2. Ravits, J. M. & La Spada, A. R. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 73, 805–811 (2009). · DOI
  3. Benatar, M. et al. ALS biomarkers for therapy development: state of the field and future directions. Muscle Nerve 53, 169–182 (2016). · DOI
  4. Chipika, R. H., Finegan, E., Li Hi Shing, S., Hardiman, O. & Bede, P. Tracking a fast-moving disease: longitudinal markers, monitoring, and clinical trial endpoints in ALS. Front. Neurol. 10, 229 (2019). · DOI
  5. Verber, N. S. et al. Biomarkers in motor neuron disease: a state of the art review. Front. Neurol. 10, 291 (2019). · DOI
  6. Rossi, D. et al. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J. Neurol. 265, 510–521 (2018). · DOI
  7. Goncalves, M. et al. Phosphoneurofilament heavy chain and vascular endothelial growth factor as cerebrospinal fluid biomarkers for ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 134–136 (2017). · DOI
  8. Lu, C. H. et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J. Neurol. Neurosurg. Psychiatry 86, 565–573 (2015). · DOI
  9. Gonzalez-Garza, M. T., Martinez, H. R., Cruz-Vega, D. E., Hernandez-Torre, M. & Moreno-Cuevas, J. E. Adipsin, MIP-1b, and IL-8 as CSF biomarker panels for ALS diagnosis. Dis. Markers 2018, 3023826 (2018). · DOI
  10. Prado, L. G. R. et al. Longitudinal assessment of clinical and inflammatory markers in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 394, 69–74 (2018). · DOI
  11. Lu, C. H. et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 3, e244 (2016). · DOI
  12. Haramati, S. et al. miRNA malfunction causes spinal motor neuron disease. Proc. Natl Acad. Sci. USA 107, 13111–13116 (2010). · DOI
  13. Emde, A. et al. Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS. EMBO J. 34, 2633–2651 (2015). · DOI · Paper page
  14. Eitan, C. & Hornstein, E. Vulnerability of microRNA biogenesis in FTD–ALS. Brain Res. 1647, 105–111 (2016). · DOI
  15. Takahashi, I. et al. Identification of plasma microRNAs as a biomarker of sporadic amyotrophic lateral sclerosis. Mol. Brain 8, 67 (2015). · DOI
  16. de Andrade, H. M. et al. MicroRNAs-424 and 206 are potential prognostic markers in spinal onset amyotrophic lateral sclerosis. J. Neurol. Sci. 368, 19–24 (2016). · DOI
  17. Sheinerman, K. S. et al. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimers Res. Ther. 9, 89 (2017). · DOI · Paper page
  18. Dobrowolny, G. et al. A longitudinal study defined circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients. Cell Death Discov. 7, 4 (2021). · DOI
  19. Benigni, M. et al. Identification of miRNAs as potential biomarkers in cerebrospinal fluid from amyotrophic lateral sclerosis patients. Neuromolecular Med. 18, 551–560 (2016). · DOI
  20. Coenen-Stass, A. M. L. et al. Evaluation of methodologies for microRNA biomarker detection by next generation sequencing. RNA Biol. 15, 1133–1145 (2018).
  21. Ogłuszka, M., Orzechowska, M., Jędroszka, D., Witas, P. & Bednarek, A. K. Evaluate Cutpoints: adaptable continuous data distribution system for determining survival in Kaplan–Meier estimator. Comput. Methods Prog. Biomed. 177, 133–139 (2019). · DOI
  22. Austin, P. C. & Tu, J. V. Bootstrap methods for developing predictive models. Am. Statistician 58, 131–137 (2004). · DOI · Paper page
  23. Westeneng, H. J. et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 17, 423–433 (2018). · DOI
  24. Steinbach, R. et al. Disease aggressiveness signatures of amyotrophic lateral sclerosis in white matter tracts revealed by the D50 disease progression model. Hum. Brain Mapp. 42, 737–752 (2021). · DOI
  25. Reichenstein, I. et al. Human genetics and neuropathology suggest a link between miR-218 and amyotrophic lateral sclerosis pathophysiology. Sci. Transl. Med. 11, eaav5264 (2019). · DOI
  26. Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14, 577–589 (2018). · DOI · Paper page
  27. Lu, C. H. et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84, 2247–2257 (2015). · DOI · Paper page
  28. Poesen, K. & Van Damme, P. Diagnostic and prognostic performance of neurofilaments in ALS. Front. Neurol. 9, 1167 (2018). · DOI
  29. Benatar, M. et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95, e59–e69 (2020). · DOI
  30. Corradi, E. et al. Axonal precursor miRNAs hitchhike on endosomes and locally regulate the development of neural circuits. EMBO J. 39, e102513 (2020). · DOI
  31. Chen, C.-Z., Li, L., Lodish, H. F. & Bartel, D. P. MicroRNAs modulate hematopoietic lineage differentiation. Science 303, 83 (2004). · DOI · Paper page
  32. Benatar, M., Wuu, J., Andersen, P. M., Lombardi, V. & Malaspina, A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann. Neurol. 84, 130–139 (2018). · DOI
  33. Puentes, F. et al. Immune reactivity to neurofilaments and dipeptide repeats in ALS progression. Preprint at https://www.biorxiv.org/content/10.1101/2020.02.25.965236v1 (2020). · DOI
  34. Puentes, F. et al. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 85, 274–278 (2014). · DOI
  35. Brooks, B. R., Miller, R. G., Swash, M., Munsat, T. L. & World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 1, 293–299 (2000). · DOI · Paper page
  36. Poesen, K. et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 88, 2302–2309 (2017). · DOI
  37. Prell, T. et al. Reaction to endoplasmic reticulum stress via ATF6 in amyotrophic lateral sclerosis deteriorates with aging. Front. Aging Neurosci. 11, 5 (2019). · DOI
  38. Kohen, R. et al. UTAP: user-friendly transcriptome analysis pipeline. BMC Bioinformatics 24, 154 (2019). · DOI
  39. Kozomara, A. & Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42, D68–D73 (2014). · DOI · Paper page
  40. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014). · DOI · Paper page
  41. Lombardi, V. et al. Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology 92, e1205–e1211 (2019). · DOI · Paper page
  42. Peng, T. et al. A BaSiC tool for background and shading correction of optical microscopy images. Nat. Commun. 8, 14836 (2017). · DOI
  43. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010). · DOI · Paper page
  44. Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N. & Golani, I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 125, 279–284 (2001). · DOI · Paper page
  45. Harrell, F. E. Jr., Lee, K. L., Califf, R. M., Pryor, D. B. & Rosati, R. A. Regression modelling strategies for improved prognostic prediction. Stat. Med. 3, 143–152 (1984). · DOI
  46. Grubbs, F. E. Procedures for detecting outlying observations in samples. Technometrics 11, 1–21 (1969). · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Magen, I., Yacovzada, N. S., Yanowski, E., Coenen-Stass, A., Grosskreutz, J., Lu, C.-H., Greensmith, L., Malaspina, A., Fratta, P., & Hornstein, E.
ORCID
Venue
Nature Neuroscience
Publisher
Springer Science and Business Media LLC
Published
2021-10-28
Volume
24
Issue
11
Pages
1534-1541
ISSN
  • 1097-6256
  • 1546-1726
DOI
10.1038/s41593-021-00936-z
Cited by
127
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review